Briacell Therapeutics Corp. - Warrants (BCTXL) closed at $0.84 on November 3, 2026, up 12.0% from the previous close, on volume of 5,651 shares (30-day average 15,228).
Data as of November 3, 2026.
No headlines found.
Globe Newswire (Tue, 3-Nov 9:00 AM ET)
Globe Newswire (Fri, 23-Oct 7:30 AM ET)
BriaCell and BriaPro to Present Four Posters at SITC 2026 Annual Meeting
Globe Newswire (Tue, 6-Oct 7:30 AM ET)
Globe Newswire (Mon, 14-Sep 7:30 AM ET)
BriaCell's Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center
Globe Newswire (Tue, 8-Sep 7:30 AM ET)
BriaCell Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+
Globe Newswire (Mon, 24-Aug 7:30 AM ET)
BriaCell Receives FDA Clearance to Initiate Bria-PROS+ Clinical Study in Prostate Cancer
Globe Newswire (Wed, 5-Aug 7:30 AM ET)
BriaCell Therapeutics Corp is a clinical-stage biotechnology company developing targeted immunotherapies to transform cancer care. Its Bria-IMT targeted immunotherapy is being developed in combination with the immune checkpoint inhibitor Retifanlimab in a pivotal Phase 3 study in metastatic breast cancer. The Company's operations focus on the research and development of its immunotherapy product candidates and related supporting activities.
Briacell Therapeutics Corp. - Warrants trades on the NASDAQ stock market under the symbol BCTXL.
As of November 3, 2026, BCTXL stock price climbed to $0.84 with 5,651 million shares trading.
BCTXL has a market cap of $0.00. This is considered a Sub-Micro Cap stock.
BCTXL support price is $.67 and resistance is $.83 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BCTXL shares will trade within this expected range on the day.
